SecBot SecBot
8-K ·Filed Jun 4, 2026

NRXPW

NRX Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001437749-26-019576
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The dilutive offering at a steep discount signals urgent capital needs for a clinical-stage biopharma with negative book value and a going-concern audit opinion. Monitor for further cash burn and potential need for additional financing. The 60-day lock-up may provide near-term price support, but the fundamental dilution overhang is significant.

DirectionBearish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals closed a firm-commitment underwritten public offering of 5,714,286 shares of common stock at $3.50 per share, raising approximately $22.3 million in gross proceeds ($20.0M base, plus full exercise of the underwriters' 857,142-share option). Net proceeds are estimated at ~$18.8M (or ~$21.6M with the option). The offering was priced at a ~24% discount to the prior close of $4.62 and is dilutive to existing shareholders, especially given the company's negative tangible book value of $(0.49) per share as of March 31, 2026. Proceeds are earmarked for working capital and general corporate purposes.

Key Financial Metrics

Deal Value
$22.3M

Key Facts

  • Offering of 5,714,286 shares at $3.50/share, with underwriters' option for 857,142 additional shares exercised in full
  • Gross proceeds of ~$22.3 million; net proceeds estimated at ~$18.8 million (or ~$21.6 million with option)
  • Purchase price to underwriters was $3.29/share, representing a $0.21/share discount
  • Offering priced at ~24% discount to last closing price of $4.62 on June 2, 2026
  • Negative tangible book value of $(0.49) per share as of March 31, 2026; new investors face immediate dilution of $3.44 per share
  • Proceeds to be used for working capital and general corporate purposes
  • 60-day lock-up on company and insider share sales
  • Offering closed on June 4, 2026

Financial Impact

~$22.3M gross proceeds raised via dilutive common stock offering at ~24% discount to market; net proceeds ~$18.8M

dilutionshare counttangible book value

Risk Factors

  • Immediate and substantial dilution to existing shareholders
  • Negative tangible book value indicates weak balance sheet
  • Clinical-stage company with no approved products and ongoing cash burn
  • Potential need for additional dilutive financing in the future

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-019576
Exhibit: ex_972572.htm0001437749-26-019576
Exhibit: ex_972121.htm0001437749-26-019576
Exhibit: ex_972122.htm0001437749-26-019576
Document: nrxp20260603_8k.htm0001437749-26-019576
Document: 0001437749-26-019576-index-headers.html0001437749-26-019576
Document: 0001437749-26-019576-index.html0001437749-26-019576
Document: 0001437749-26-019576.txt0001437749-26-019576

Track record

4 reports on NRXPW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jun 4, 202623w ago 8-K Bearish 6/10 Viewing No price data
  2. Jun 3, 202623w ago 424B5 Bearish 6/10 No price data
  3. Jun 2, 202623w ago 424B5 Bearish 6/10 No price data
  4. May 22, 202625w ago 25-NSE Bearish 8/10 Entry $0.0142 to $0.0142 · 0.00% +1.21% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026